- Current report filing (8-K)
May 08 2012 - 4:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 2, 2012
ALSERES PHARMACEUTICALS, INC.
(Exact Name of Registrant as
Specified in Charter)
|
|
|
|
|
|
|
Delaware
|
|
0-6533
|
|
87-0277826
|
|
(State or Other Jurisdiction of Incorporation
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
|
239 South Street, Hopkinton, Massachusetts
|
|
01748
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (508) 497-2360
(Former Name or Former Address,
if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 8.01.
|
Other Information
|
On May 2, 2012
the Company received notice that Biostorage Technologies, Inc. had filed a lawsuit in Marion Superior/Circuit Court, Marion County, Indiana seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $119,363. The Company
believes that the amounts claimed are significantly overstated and not in fact owed and will pursue all legal and equitable remedies available to it to defend this claim.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Alseres Pharmaceuticals, Inc.
|
|
|
|
|
|
|
Date: May 8, 2012
|
|
|
|
By:
|
|
/s/ Kenneth L. Rice, Jr.
|
|
|
|
|
|
|
|
Kenneth L. Rice, Jr.
Executive
Vice President, Finance and Administration and Chief Financial Officer
|
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Dec 2024 to Dec 2024
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Dec 2023 to Dec 2024
